Cargando…

The value of SPECT/CT imaging of lacrimal glands as a means of assessing the activity of Graves’ orbitopathy

BACKGROUND: Graves’ orbitopathy (GO) is an autoimmune disease with mechanical impairment of orbital muscles and lacrimal gland dysfunction. The frequently used methods of assessing GO activity include Clinical Activity Score (CAS), CT, and MRI. These approaches are mainly associated with orbital mus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Ru-Xuan, Shi, Ting-Ting, Luo, Sha, Liu, Yun-Fu, Xin, Zhong, Yang, Jin-Kui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859942/ https://www.ncbi.nlm.nih.gov/pubmed/35015696 http://dx.doi.org/10.1530/EC-21-0590

Ejemplares similares

Isolated Lacrimal Gland Enlargement in Thyroid-Related Orbitopathy
por: Yahalomi, Tal, et al.
Publicado: (2021)

Efficacy of (99m)Tc-DTPA SPECT/CT in diagnosing Orbitopathy in graves’ disease
por: Szumowski, Piotr, et al.
Publicado: (2019)

Deep learning-based diagnosis of disease activity in patients with Graves’ orbitopathy using orbital SPECT/CT
por: Yao, Ni, et al.
Publicado: (2023)

Lacrimal gland enlargement as an early clinical or radiological sign in thyroid orbitopathy
por: Khu, James, et al.
Publicado: (2016)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Monitoring and Predicting Treatment Response of Extraocular Muscles in Grave's Orbitopathy by (99m)Tc-DTPA SPECT/CT
por: Jiang, Chengzhi, et al.
Publicado: (2021)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Teprotumumab: a disease modifying treatment for graves’ orbitopathy
por: Ting, Michelle, et al.
Publicado: (2020)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

In vivo confocal microscopy assessment of meibomian glands microstructure in patients with Graves’ orbitopathy
por: Cheng, Shengnan, et al.
Publicado: (2021)

The Clinical Features of Graves' Orbitopathy with Elevated Intraocular Pressure
por: Fan, Shu-Xian, et al.
Publicado: (2021)

Zirconium-89 labelled rituximab PET-CT imaging of Graves’ orbitopathy
por: de Keizer, Bart, et al.
Publicado: (2019)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

The Potential Link between Gut Microbiota and Serum TRAb in Chinese Patients with Severe and Active Graves' Orbitopathy
por: Shi, Ting-Ting, et al.
Publicado: (2019)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Rapamycin improves Graves’ orbitopathy by suppressing CD4(+) cytotoxic T lymphocytes
por: Zhang, Meng, et al.
Publicado: (2023)

Identifying and Validating Genes with DNA Methylation Data in the Context of Biological Network for Chinese Patients with Graves' Orbitopathy
por: Shi, Ting-Ting, et al.
Publicado: (2019)

A Pathway Analysis Based on Genome-Wide DNA Methylation of Chinese Patients with Graves' Orbitopathy
por: Xin, Zhong, et al.
Publicado: (2019)

Endoscopic intranasal orbital decompression in the course of Graves’ orbitopathy
por: Krzeski, Antoni, et al.
Publicado: (2013)

Association between Polymorphisms in the TSHR Gene and Graves' Orbitopathy
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2014)

Not All Orbitopathy Is Graves’: Discussion of Cases and Review of Literature
por: Boddu, Neeraja, et al.
Publicado: (2017)

Factors associated with severity of orbitopathy in patients with Graves' disease
por: Nabi, Tauseef, et al.
Publicado: (2020)

Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy
por: Bednarczuk, Tomasz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f6di3pmjhb2d9h9efp7876ming